Bladder Cancer Therapeutics and Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics), by Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)), by Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types), By Region, and
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBladder Cancer Therapeutics and Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics), by Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)), by Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types), By Region, and
| Forecast Period | 2024-2028 |
| Market Size (2022) | 450 million |
| CAGR (2024-2028) | 7.50% |
| Fastest Growing Segment | Chemotherapy Segment |
| Largest Market | North America |
Market Overview
Global Bladder Cancer Therapeutics and Diagnostics Market has valued at USD 450 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2028. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.
Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.
Key Market Drivers
Increasing Innovative Therapies
Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.
Nanotechnology is used to develop nanoscale drug delivery systems that can target cancer cells more precisely, enhance drug delivery efficiency, and reduce side effects. AI and machine learning algorithms are applied to medical imaging data to assist radiologists and pathologists in detecting and diagnosing cancer more accurately. AI can analyze large datasets, identify patterns, and aid in treatment planning. Onco-genomics involves the genomic profiling of tumors to identify specific genetic mutations and alterations. This information guides treatment decisions and helps identify potential therapeutic targets. Epigenetic therapies focus on modifying gene expression through changes in DNA methylation and histone modifications. These therapies aim to reverse or silence cancer-promoting genes. Building on CAR-T cell therapy, CAR-NK cell therapy uses natural killer (NK) cells that have been genetically engineered to target cancer cells. It offers potential advantages, including reduced side effects. Patient-derived organoids are three-dimensional cultures of cancer cells that mimic the patient's tumor. They are used for drug testing, personalized treatment selection, and studying cancer biology. This factor will help in the development of Global Bladder Cancer Therapeutics and Diagnostics Market.
Growing Aging Population
Cancer is predominantly a disease of aging, with the risk of developing cancer rising significantly as people grow older. Many types of cancer, such as breast, prostate, lung, and colorectal cancer, are more common in older individuals. As the population ages, the overall incidence of cancer increases. This leads to a greater number of cancer cases, necessitating a higher demand for diagnostic tests, treatments, and ongoing monitoring. Older cancer patients often have complex healthcare needs due to the presence of multiple chronic conditions or comorbidities. This complexity can drive demand for comprehensive diagnostics and specialized treatments tailored to the individual. Early cancer detection is crucial for better outcomes. The aging population may benefit from increased screening and diagnostic efforts to identify cancer at an earlier, more treatable stage. Older patients may have unique treatment challenges, including tolerance to therapies, potential drug interactions with other medications, and age-related physiological changes. These factors necessitate a more tailored approach to cancer therapeutics.
Rising Bladder Cancer Incidence
Bladder cancer is a global health concern characterized by the abnormal growth of cells in the bladder lining. The demographic shift towards an aging population is a significant driver of bladder cancer incidence. As individuals age, their risk of developing bladder cancer increases. The older population is more likely to experience this disease, leading to a higher overall incidence rate. Smoking remains one of the most well-established risk factors for bladder cancer. The carcinogens found in tobacco smoke can accumulate in the bladder, leading to cellular damage over time. Despite awareness campaigns, tobacco use persists, contributing to the incidence of bladder cancer. Certain occupations, such as those involving exposure to industrial chemicals and carcinogens, have been linked to an increased risk of bladder cancer. Workers in industries like chemical manufacturing, textile, and printing are particularly vulnerable. Environmental pollutants, including contaminated drinking water sources, exposure to industrial waste, and agricultural chemicals, have been associated with bladder cancer. Prolonged exposure to these substances can elevate the risk of developing the disease. Bladder cancer is more common in men than in women. This gender disparity contributes to the higher overall incidence rate, as men are generally at greater risk due to biological and behavioral factors. Genetic predisposition can play a role in bladder cancer incidence. Individuals with a family history of the disease may have an increased susceptibility.
The rising incidence of bladder cancer places a substantial burden on healthcare systems worldwide. The diagnosis, treatment, and long-term care of bladder cancer patients require significant resources. The economic costs associated with bladder cancer are substantial, encompassing healthcare expenses, lost productivity, and the financial burden on individuals and families affected by the disease. Bladder cancer can profoundly affect the quality of life of those diagnosed. Patients often undergo invasive treatments, such as surgery, chemotherapy, and radiation therapy, which can lead to physical and emotional challenges. Although bladder cancer is often treatable when detected early, the rise in incidence may also lead to increased mortality rates if timely diagnosis and effective treatments are not accessible. Encouraging smoking cessation programs and policies can have a significant impact on reducing bladder cancer incidence. Providing resources and support for individuals looking to quit smoking is essential. Promoting regular health check-ups and cancer screenings can lead to the early detection of bladder cancer, improving the chances of successful treatment. Strengthening environmental regulations and monitoring efforts to reduce pollution and chemical exposure is vital for preventing environmentally induced bladder cancer. This factor will pace up the demand of Global Bladder Cancer Therapeutics and Diagnostics Market
Key Market Challenges
High Treatment Costs
The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.
Health Disparities
Limited access to healthcare services, including early cancer detection and timely treatment, is a significant driver of health disparities. Individuals with limited access to medical facilities are often diagnosed at more advanced stages of bladder cancer, leading to poorer outcomes. Disparities exist in the utilization of cancer screening and early detection services. Some populations, due to socioeconomic factors or lack of awareness, may not undergo recommended screenings, resulting in delayed diagnosis. Socioeconomic factors, such as income, education, and employment status, play a significant role in health disparities. Individuals with lower socioeconomic status may have less access to healthcare resources and face barriers to receiving timely and high-quality bladder cancer care. Disparities in access to healthcare services are often more pronounced in rural or underserved areas. Patients in these regions may face longer travel distances to reach specialized cancer centers, resulting in delays in diagnosis and treatment initiation. Racial and ethnic minorities may experience disparities in bladder cancer incidence, treatment options, and outcomes. Factors such as cultural beliefs, language barriers, and discrimination can contribute to these disparities. Lack of health insurance or underinsurance can lead to disparities in access to bladder cancer diagnostic tests, treatments, and follow-up care. Uninsured or underinsured individuals may delay seeking care due to financial concerns.
Key Market Trends
Minimally Invasive Surgical Techniques
Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.
Segmental Insights
Therapeutics Insights
In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market largest share was held by Chemotherapy segment and is predicted to continue expanding over the coming years.
Diagnostics Insights
In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market dominated by Cystoscopy segment and is predicted to continue expanding over the coming years.
Cancer Type Insights
In 2022, the Global Bladder Cancer Therapeutics and Diagnostics Market largest share was held by Transitional Cell Bladder Cancer segment in the forecast period and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Bladder Cancer Therapeutics and Diagnostics Market in 2022.
Recent Developments
- In July 2022, The FDAhas accepted ImmunityBio, Inc.'s Biologics License Application (BLA) for reviewin relation to its antibody cytokine fusion protein as a treatment for patientswith non-muscle-invasive bladder cancer carcinoma in situ (CIS) that isunresponsive to BCG and may or may not have Ta or T1 illness. Severalinvestigations of the experimental medicine, including the ongoing QUILT 3.032study, produced encouraging results, which encouraged ImmunityBio, a topclinical-stage immunotherapy business, to file the BLA. This N-803 and BCGcombination is ImmunityBio's first BLA to advance to this FDA review acceptancelevel. This represents a significant step towards realizing ImmunityBio'sobjective of treating cancer patients differently by stimulating their innateimmune systems rather than using high-dose chemotherapy. The unique method ofaction of N-803 promotes the growth of NK and T cells, which are components ofthe innate and adaptive immune systems. By doing this, N-803 enhances theimmune response brought on by BCG in the case of bladder cancer or a checkpointinhibitor in other circumstances.
- In July 2022, using its ClarityDX diagnosticplatform, Nanostics Inc., a company that develops precision health diagnostics,has started prospective clinical research to validate ClarityDX Bladder, arevolutionary and less invasive bladder cancer diagnostic test. The study willenrol participants at locations in Alberta and Northern Ontario thanks to acollaboration between DynaLIFE Medical Labs and the University of Alberta'sAlberta Prostate Cancer Research Initiative (APCaRI). Through the AlbertaInnovates AICE-Concepts Program, a $600,000 financial commitment is made insupport of the project. According to preliminary research with 142 patients,ClarityDX Bladder might distinguish between patients with bladder cancer andhealthy people with greater accuracy.
Key Market Players
- Ameritech DiagnosticReagent (Jiaxing)Co., Ltd
- Bristol-Myers SquibbCompany
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer Inc.
- Abbott Inc.
- Endo Pharmaceuticals Inc.
- Johnson & Johnson(Janssen Pharmaceutical)
- Merck & Co. Inc
- Astellas Pharma Inc.
| By Therapeutics | By Diagnostics | By Cancer Type | By Region | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy